Bank of New York Mellon
HOWL icon

Bank of New York Mellon’s Werewolf Therapeutics HOWL Stock Holding History

Bank of New York Mellon’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-62,407
Closed -$60.7K – 4193
2025
Q1 		$60.7K Sell
62,407
-8,893
-12% -$11.6K ﹤0.01% 4041
2024
Q4 		$106K Buy
71,300
+13,372
+23% +$27.3K ﹤0.01% 4028
2024
Q3 		$123K Sell
57,928
-9,716
-14% -$22.1K ﹤0.01% 3988
2024
Q2 		$165K Buy
+67,644
New +$325K ﹤0.01% 3980
2022
Q2 		– Sell
-68,338
Closed -$301K – 4647
2022
Q1 		$301K Buy
68,338
+3,555
+5% +$24.9K ﹤0.01% 4017
2021
Q4 		$772K Buy
64,783
+34,994
+117% +$528K ﹤0.01% 3536
2021
Q3 		$512K Buy
29,789
+7,576
+34% +$129K ﹤0.01% 3793
2021
Q2 		$387K Buy
+22,213
New +$304K ﹤0.01% 3890

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of New York Mellon's HOWL Position: Q2 2025 in Review

Bank of New York Mellon sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 62,407 shares — an estimated $60.7K sold.

Bank of New York Mellon first reported a position in HOWL in Q2 2021 and held it in 8 quarters. The position peaked at $772K in Q4 2021. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Bank of New York Mellon reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 62,407 Werewolf Therapeutics shares in Q2 2025, an estimated $60.7K.
  • Bank of New York Mellon first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 8 quarters.
  • Bank of New York Mellon's Werewolf Therapeutics position peaked at $772K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.